This monograph does not cover the use of progesterone for assisted reproduction, threatened miscarriage or the prevention of preterm birth.
Issues for surgery
For hormonal replacement therapy (in conjunction with oestrogen) – risk of menopausal symptoms, e.g. hot flushes, if discontinued pre-operatively.
For premenstrual syndrome [unlicensed]– increase in anxiety, moodiness, and increased sensitivity to seizures if discontinued abruptly.
Increased risk of venous thromboembolism (VTE), if used in combination with oral oestrogen and continued – see Further Information.
Advice in the perioperative period
Elective & emergency surgery
Oral and injectable preparations
Continue.
Vaginal preparations
Continue (unless undergoing gynaecological procedure and advised otherwise by surgeon).
Post-operative advice
Ensure VTE risk assessment completed.
Progesterone should be discontinued in the event of a post-operative venous thromboembolism – see Further information.
Interactions with common anaesthetic agents
The UK manufacturer of Utrogestan® notes that it may increase the arrhythmogenic potential of bupivacaine, but the clinical significance of this reaction is unknown.
Interactions with other common medicines used in the perioperative period
None.
Further information
Use of oestrogens is associated with an increased risk of VTE; however, the link with the use of progesterone remains unclear. The type of progesterone significantly affects VTE. Strong evidence shows that micronised progesterone has no effect on clotting factors. In addition, a meta-analysis has shown that in users of transdermal oestrogen, there was no change in VTE risk in women using micronised progesterone. In patients with known risk factors for VTE, the combination of transdermal oestrogen and micronised progesterone offers a safe option that is unlikely to significantly increase VTE risk.
If post-operative VTE occurs, discontinue all systemic hormonal preparations and seek specialist advice before considering recommencement.
References
Besins Healthcare (UK) Ltd. Summary of Product Characteristics – Utrogestan® (progesterone) 100mg Capsules [Internet]. n.d. [cited 2025 Apr 18]. Available from: https://www.medicines.org.uk/ [date of revision of the text 12th March 2025]
British Menopause Society. BMS & WHC’s 2020 recommendations on hormone replacement therapy in menopausal women (Updated September 2025) 2025 [cited 2025 Apr 18]. Available from: https://thebms.org.uk/wp-content/uploads/2023/10/02-BMS-ConsensusStatement-BMS-WHC-2020-Recommendations-on-HRT-in-menopausal-women-SEPT2023-A.pdf
Joint Formulary Committee. British National Formulary (BNF) [Internet]. London: BMJ Group and Pharmaceutical Press; n.d. [cited 2026 Aug 10]. Available from: https://bnf.nice.org.uk/
L.D. Collins & Co. Ltd. Summary of Product Characteristics – Cyclogest® (progesterone) 200mg pessaries [Internet]. n.d. [cited 2026 July 13]. Available from: https://www.medicines.org.uk/ [date of revision of the text 5th February 2026]
Royal Pharmaceutical Society. Stockley’s Drug Interactions [Internet]. London: Royal Pharmaceutical Society; 2025 [cited 2025 Mar 30]. Available from: https://www.medicinescomplete.com
Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:3071–8
Scarabin P-Y. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric. 2018;21(4):341–5